Non-vitamin K antagonist oral anticoagulants (NOAC) in the treatment of venous thromboembolism

REVIEW, September 2015, VOL IV ISSUE I, ISSN 2042-4884
10.5083/ejcm.20424884.142 , Cite or Link Using DOI
Creating a Digital Object Identifier Link

A digital object identifier (DOI) can be used to cite and link to electronic documents. A DOI is guaranteed never to change, so you can use it to link permanently to electronic documents.

To find a document using a DOI

  1. Copy the DOI of the document you want to open.
    The correct format for citing a DOI is as follows: doi:10.1016/S0140-6736(08)61345-8
  2. Open the following DOI site in your browser:
    dx.doi.org
  3. Enter the entire DOI citation in the text box provided, and then click Go.
    The document that matches the DOI citation will display in your browser window.

The DOI scheme is administered by the International DOI Foundation. Many of the world's leading publishers have come together to build a DOI-based document linking scheme known as CrossRef.

Sebastian Werth, Jan Beyer-Westendorf

ABSTRACT

In case of venous thromboembolism (VTE) effective anticoagulation is needed.
The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) for VTE therapy offers new treatment options and, in general, simplifies VTE therapy compared to the concept of LMWH/VKA. At the same time, NOACs may help to improve the clinical outcome of patients with VTE as trial results consistently indicated the reduction in major bleeding complications. There are several
reasons to use NOAC in special populations but it is crucial that prescribers of NOACs are educated both on the advantages and limits of these new anticoagulants.

This review is focused on the role of NOACs VTE treatment. The publication illustrates NOAC treatment in pretherapy (suspicious VTE), initial therapy and in maintenance treatment (secondary prevention) and in extended secondary prevention.

Additionally, the role of NOAC in special populations like fragile patients, renally-impaired patients, cancer patients, and patients with acquired or hereditary thrombophilic disorders were highlighted. Potentially unsuitable patient groups for NOAC therapy were discussed.